Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. It usually
has a comparatively benign course. If properly executed, radioiodine therapy can provide an …

Radioiodine (RAI) is a pivotal important treatment for patients with metastatic differentiated
thyroid cancer (DTC). In order to determine when a patient will no longer respond to RAI …

Context: Pediatric differentiated thyroid cancer (DTC) patients frequently present with lymph
node and/or distant (lung) metastases. Such patients warrant an aggressive treatment …

Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully
used for more than 70 years. However, there is still plenty of controversy surrounding the …

Background: Radioactive iodine (RAI) remnant ablation has been used to eliminate normal
thyroid tissue and may also facilitate monitoring for persistent or recurrent thyroid carcinoma …

Background Approximately one third of the patients with differentiated thyroid cancer (DTC)
who develop structurally-evident metastatic disease are refractory to radioactive iodine …

Thefirst reports of radionuclide therapy for thyroid disease used 130I, but 131I rapidly
became the favoured radionuclide with beta-and gamma-ray emissions and a half-life …

Background: The management of aggressive and progressing metastatic differentiated
thyroid cancer (DTC) is very difficult, and the determination as to when such patients are …

In general, juvenile differentiated thyroid carcinoma (DTC) demonstrate indolent
characteristics and favorable prognosis are observed in comparison with many other …

Introduction The purpose of the present guidelines on the radioiodine therapy (RAIT) of
differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear …